Driehaus Capital Management LLC Takes $1.46 Million Position in Maze Therapeutics, Inc. $MAZE

Key Points

• Driehaus Capital Management LLC acquired 132,115 shares of Maze Therapeutics, Inc., valued at approximately $1.45 million, representing about 0.30% of the company's shares.
• Maze Therapeutics is receiving positive attention from analysts, with HC Wainwright assigning a buy rating and a price target of $34.00, while the company holds an average ratings of Buy with an average target price of $25.60.
• The company recently reported earnings of ($0.77) per share, slightly surpassing analysts' consensus estimate of ($0.79) by $0.02.

Driehaus Capital Management LLC purchased a new position in shares of Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 132,115 shares of the company's stock, valued at approximately $1,455,000. Driehaus Capital Management LLC owned approximately 0.30% of Maze Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently made changes to their positions in MAZE. General Catalyst Group Management LLC purchased a new stake in shares of Maze Therapeutics during the first quarter worth approximately $11,405,000. Bessemer Group Inc. purchased a new stake in shares of Maze Therapeutics during the first quarter worth approximately $5,305,000. Bank of New York Mellon Corp purchased a new stake in shares of Maze Therapeutics during the first quarter worth approximately $190,000. New York State Common Retirement Fund purchased a new stake in shares of Maze Therapeutics during the first quarter worth approximately $25,000. Finally, Alphabet Inc. purchased a new stake in Maze Therapeutics in the 1st quarter valued at $26,561,000.

Maze Therapeutics Stock Performance

Shares of NASDAQ MAZE traded up $0.84 during mid-day trading on Friday, reaching $15.88. 309,623 shares of the company's stock were exchanged, compared to its average volume of 310,347. Maze Therapeutics, Inc. has a 52-week low of $6.71 and a 52-week high of $19.19. The company's 50-day moving average is $14.55 and its 200-day moving average is $12.01.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.77) earnings per share for the quarter, topping analysts' consensus estimates of ($0.79) by $0.02.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. HC Wainwright assumed coverage on Maze Therapeutics in a report on Wednesday, July 23rd. They issued a "buy" rating and a $34.00 target price for the company. Wall Street Zen upgraded Maze Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 16th. BTIG Research assumed coverage on Maze Therapeutics in a report on Tuesday. They issued a "buy" rating and a $30.00 target price for the company. Finally, Wedbush assumed coverage on Maze Therapeutics in a report on Tuesday, July 8th. They issued an "outperform" rating and a $17.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating and six have given a Buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $26.33.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.